Litigation Details for Vytacera Bio, LLC v. CytomX Therapeutics, Inc. (D. Del. 2020)
✉ Email this page to a colleague
Vytacera Bio, LLC v. CytomX Therapeutics, Inc. (D. Del. 2020)
Docket | ⤷ Try a Trial | Date Filed | 2020-03-03 |
Court | District Court, D. Delaware | Date Terminated | |
Cause | 35:1 Patent Infringement | Assigned To | Leonard Philip Stark |
Jury Demand | Plaintiff | Referred To | Christopher J. Burke |
Patents | 9,775,913 | ||
Link to Docket | External link to docket |
Biologic Drugs cited in Vytacera Bio, LLC v. CytomX Therapeutics, Inc.
Details for Vytacera Bio, LLC v. CytomX Therapeutics, Inc. (D. Del. 2020)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2022-05-09 | 155 | Order - -Memorandum and Order | terms in U.S. Patent Nos. 8,809,504 (the “’504 patent”) and 9,775,913 (the “’913 patent”); WHEREAS… 1 In the ’913 patent, the “biologically active agent” is an “antibody.” (’913 patent cls. 1, 22) There…antibody” of the ’913 patent is a “biologically active agent” as described in the patents, and the Court’s …explicit definition of the RD term in the patents.”) (citing ’504 patent at 6:5-7) 5 The Court finds it…term “recognition domain” in the ’504 and ’913 patents; WHEREAS, on April 7, 2022, CytomX objected | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |